See the latest news and media coverage for Edwards. We track all announcements, press releases, and industry mentions in real time, all in one place.
Structural heart medical device manufacturer
edwards.comLast updated
In short: Edwards reported strong Q2 2026 financial results, beating analysts' estimates and raising its full-year sales and earnings guidance.
Second quarter sales grew 13.6% to $1.74 billion, driven by TAVR and structural heart therapies. The company increases its full-year constant currency sales growth forecast to 10-11%. Updated financial projections confirm adjusted EPS guidance of $2.95 to $3.05.
The board approved the split after evaluating employee interest and rising share prices that limit accessibility for newer investors.
Sales rose to $1.74B, driven by TAVR and TMTT; adjusted EPS of $0.78 beat expectations.
The earnings release includes forward-looking statements and non-GAAP reconciliations.
IRVINE, Calif. -- (BUSINESS WIRE)--Sep. 10, 2026-- Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for...
Edwards Lifesciences stock closed at USD 86.18 on September 9, 2026, modestly below recent highs near USD 89 as the company lifts its 2026 revenue...
Edwards Lifesciences Upgraded to Buy by UBS On October 24, 2023, UBS has upgraded Edwards...
On July 23, Edwards Lifesciences Corporation (NYSE:EW) delivered second-quarter 2026 net sales of $1.74 billion, up 13.6% year over year (12.5% on a constant currency...
Track Edwards and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Edwards and other trending companies.